Apixaban: direct factor Xa inhibitor

5mg twice daily
2.5 mg daily if two of the following are present: age >80 years, body weight <60kg, creatinine >

Indication: Patients with non-valvular atrial fibrillation requiring anticoagulation
Suitable candidates for treatment: patients with unstable INRs, complicated drug regimens, high risk for intracranial bleeding, and difficulty in have INRs monitored regularly

Do not use for patients with the following:
• Severe renal impairment
• End stage renal disease on Hemodialysis (until more information is available)
• Mechanical heart valves
• Acute stroke (within 14 days or disabling stroke within 6 months)
• Infective endocarditis
• Acute liver disease (LFTs >2 times the upper limit of normal)
• Concomitant P-glycoprotein inducers (rifampin, St. Johns Wort, see drug drug interactions for more)
• Active pathologic bleed or GI bleeding within past year or recurrent GI bleed
• Pregnancy
• Inability to swallow capsules (capsules may not be opened or crushed)
• History of hypersensitivity reaction

For more information, including switching between anticoagulant regimens, drug-drug interactions, management with bleeding, and surgical considerations, please follow the link to the European Heart Rhythm Association’s Practical Guide on the use of new oral anticoagulants: http://eurheartj.oxfordjournals.org/content/early/2013/04/25/eurheartj.eht134

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s